Compare · HOOK vs LUMO
HOOK vs LUMO
Side-by-side comparison of HOOKIPA Pharma Inc. (HOOK) and Lumos Pharma Inc. (LUMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HOOK and LUMO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LUMO is the larger of the two at $78.6M, about 1.9x HOOK ($41.0M).
- HOOK has more recent analyst coverage (11 ratings vs 2 for LUMO).
- Company
- HOOKIPA Pharma Inc.
- Lumos Pharma Inc.
- Price
- $0.87-3.61%
- $4.35+0.35%
- Market cap
- $41.0M
- $78.6M
- 1M return
- +0.00%
- -
- 1Y return
- -8.41%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2011
- News (4w)
- 0
- 0
- Recent ratings
- 11
- 2
HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Lumos Pharma Inc.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.
Latest HOOK
- HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
- Chief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)
- SEC Form 15-12G filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form 25 filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.
Latest LUMO
- Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
- SEC Form 15-12G filed by Lumos Pharma Inc.
- Chief Executive Officer Hawkins Richard J returned 757,562 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Zoth Lota S. returned 2,187 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Mckew John C. returned 13,153 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Johnson Chad Allen returned 1,076 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Van Es-Johansson An returned 1,100 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Raffin Thomas A. returned 9,406 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Pitukcheewanont Pisit Duke returned 16,836 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Lalande Kevin M. returned 731,522 shares to the company, closing all direct ownership in the company (SEC Form 4)